CORAL GABLES, Fla., May 21, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that patient enrollment in its CPP-109 vigabatrin Phase II(b) clinical trial has reached its goal of 200 cocaine dependent subjects. The Company anticipates that screening of all remaining subjects will be completed this week and the total number enrolled will be approximately 210. Top-line results of the clinical trial are expected to be available early in the first quarter of 2013.
